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ABSTRACT
Despite the close association between Kaposi’s sarcoma (KS) and immune
dysfunction, it remains unclear whether tumor infiltrating immune cells (TIIC),
by their absence, presence, or dysfunction, are mechanistically correlated with KS
pathogenesis. Therefore, their potential capacity to serve as prognostic biomarkers
of KS disease progression or control is unclear. Because epidemic-KS (EpKS) occurs
with HIV-1 co-infection, it is particularly important to compare TIIC between EpKS
and HIV-negative African endemic-KS (EnKS) to dissect the roles of HIV-1 and Kaposi
Sarcoma-associated herpesvirus (KSHV) in KS pathogenesis. This cross-sectional
study of 13 advanced KS (4 EnKS, 9 EpKS) patients and 3 healthy controls utilized
single-color immunohistochemistry and dual-color immunofluorescence assays to
characterize and quantify KSHV infected cells in relation to various TIIC in KS biopsies.
Analysis of variance (ANOVA) and Mann-Whitney tests were used to assess differences
between groups where P-values < 0.05 were considered significant. The abundance
of KSHV infected cells was heterogeneous in KS biopsies. Despite the presence of
T-cell chemoattractant chemokine CxCL-9 in biopsies, CD8+ T-cells were sparsely
distributed in regions with evident KSHV infected cells but were readily detectable in
regions devoid of KSHV infected cells (P < 0.0001). CD68+ (M1) macrophages were
evenly and diffusely distributed in KS biopsies, whereas, the majority of CD163+ (M2)
macrophages were localized in regions devoid of KSHV infected cells (P < 0.0001).
Overall, the poor immune cell infiltration or co-localization in KS biopsies independent
of HIV-1 co-infection suggests a fundamental tumor immune evasion mechanism that
warrants further investigation.

INTRODUCTION

the precise nature of this dysregulation and how it drives
KS remains poorly understood. Pathogenetic mechanisms
driving African endemic-KS (EnKS), which is responsible
for an estimated 4–10% of African adult cancers [3, 4], are
even less clear, since EnKS occurs in both genders as well
as children and in the absence of HIV-1 infection or other

Increased incidence of Kaposi’s sarcoma (KS) in
the HIV-1 infected (EpKS), transplant recipients, and in
the elderly, implies that immune dysregulation or immune
suppression plays a role in tumorigenesis [1, 2]. However,
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known immune dysfunctions. Indeed we have shown that
KSHV viremia and humoral responses in EnKS show few
significant differentials in comparison to those in EpKS
[5].
Tumor infiltrating immune cells (TIIC) are
indicators of tumor-related immune responses and are
therefore often the targets of cancer immunotherapy
[6]. For example, CD8+ T-cell infiltration in lung cancer
and melanomas has been used as prognostic tool [7, 8].
In addition, tumor infiltration of myeloid lineage cells
with a pro-inflammatory macrophage phenotype is also
associated with tumor prognosis. Pro-inflammatory
(M1) macrophages promote cytotoxic and anti-tumor
CD8 and CD4 responses, whereas anti-inflammatory M2
macrophages contribute to Th2 responses, tissues repair
and tumor growth [9–11]. Promoting a switch from the
M2 to M1 phenotype in tumors and induction of proinflammatory cytotoxic T-cell responses has also been
shown to slow or stop cancer growth [12]. Therapeutically,
isolation of TIIC, such as T-cells, from tumors, followed
by ex vivo expansion, antigenic stimulation and transfer
back to the same patient is now a viable treatment strategy
in cancers like melanoma and cervical carcinoma [13, 14].
Defining the value of TIIC as cancer prognostic marker
is therefore an active area of research for a number of
human cancers [7, 15, 16]. Nevertheless, despite the close
association between KS and immune dysfunction [5], it
remains unclear whether TIIC are a critical component in
KS pathogenesis, and whether their absence, presence, or
dysregulation could serve as a prognostic biomarker of KS
disease progression or control. This is particularly relevant
for comparison of EpKS to EnKS where the disease
presentation, pathology and humoral immune parameters
appear to be highly similar and therefore, the direct or
indirect role of HIV-1 in KS remains unclear [5].
Our recent transcriptomic comparison of KS lesions
to normal skin from the same individuals, revealed that KS
lesions exhibited elevated expression of CxCL-9, CXCL10 and CXCL-11 [17]. Since these chemokines are known
to create chemotactic gradients for T-cell recruitment
to sites of infection or loss of homeostasis [18], we
asked whether CxCL-9 transcript upregulation was also
evident at the protein levels in KS lesions, and if such
over-expression correlated with immune cell infiltration
into the KS microenvironment. Additionally, because
transcriptomics revealed little or no HIV-1 transcription
in EpKS lesions (16), we sought to investigate potential
indirect effects of HIV-1 immune dysregulation in KS,
through comparison of immune cell infiltration between
EpKS and EnKS patients. We biopsied EpKS and EnKS
patients from sub-Saharan Africa (SSA) to explore the
relationships between chemokine expression, Kaposi’s
sarcoma-associated herpesvirus (KSHV)-infected cells,
TIIC and HIV-1 co-infection. Our study reveals poor
immune cell infiltration in most KS tissues and lack of colocalization between TIIC and regions with demonstrable
www.oncotarget.com

KSHV infection but detected no differentials in immune
cell infiltration as a result of HIV-1 co-infection.

RESULTS
Characteristics of study subjects
To investigate the relationship between KSHV
infected cells and TIIC in KS biopsies, samples with
LANA+ cells demonstrable by IHC were utilized. A total
of 13 KS cases (4 EnKS and 9 EpKS) and 3 normal skin
donors were evaluated for this study. Ages in the cohort
ranged from 27 to 84 with a median of 42 years (Table 1).
The self-reported duration of KS ranged from 2 months
to 3 years at the time of recruitment and was similar
between EnKS and EpKS at a median of 6 and 3 months,
respectively. EpKS patients were all ART experienced
with undetectable plasma HIV-1 load, excepting patient
C038 and 21242 who were on ART for less than a month
and patient C3097 who was experiencing ART failure.
Consistent with the most common presentation of KS in
the region [19], most patients had nodular morphotype KS
lesions on the extremities (Table 1).

Heterogeneous expression of LANA in KS
biopsies
To investigate the relationships between KSHV
infected cells and TIIC, we first defined ‘infected cells’ as
those evincing a punctate nuclear KSHV LANA staining
pattern by IHC [20]. LANA is responsible for maintaining
the KSHV episome in infected cells during latency and
is also expressed in lytic reactivation [21]. In all KS
biopsies, characteristic spindle-morphology cells were
evident throughout the biopsy; however, we observed
heterogeneous distributions of LANA+ cells. While LANA
was not detectable in all spindle cells, some biopsies had
a high abundance of LANA+ cells. KS biopsies with
medium and low frequency LANA+ cell distributions were
also common (Figure 1A).

LANA+ cells in KS biopsies express endothelial
cells marker
Studies have suggested that the majority of KSHV
infected cells in tumors express markers of endothelial
cell lineage including CD34 [22, 23]. To confirm the
endothelial lineage of KSHV infected cells in the biopsies
studied, we utilized DIF staining to simultaneously detect
LANA in the nuclei and CD34 on the cell surface. We
found that majority of the LANA+ cells in KS biopsies
were CD34+ and thus appear to be of endothelial origin,
whereas in normal skin, the CD34+ cells were confined to
distinct vasculature and LANA was absent. Interestingly,
although the majority of LANA+ cells appeared to be
endothelial in origin, there were some CD34 negative
1557
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Table 1: Characteristics of study subjects
ID
C3096
C3107
C3138
C063
C3057
C3094
C3097
C3104
C216
C038
21227
21230
21242
21650
21651
21652

Gender

Age

M
M
M
M
F
M
F
F
F
F
M
M
M
M
M
F

27
84
72
58
37
45
37
39
61
44
40
34
44
42
42
38

HIV-1 Status KS Duration**
—
—
—
—
+
+
+
+
+
+
+
+
+
—
—
—

3 months
2 years
NR
6 months
3 months
2 months
4 months
2 months
5 months
3 months
2 months
3 years
3 months

ART
Duration
NA
NA
NA
NA
1 month
2 years
7 years
2 months
6 months
2 days
3 months
3 years
21 days

Plasma HIV1 load*
NA
NA
NA
NA
< 50
< 50
1.4E+06
< 50
NR
1.5E+04
< 50
< 50
3.2E+05
Normal Skin
Normal Skin
Normal Skin

Lesion
Type
Nodular
Nodular
Nodular
Nodular
Plaque
Nodular
Nodular
Nodular
Nodular
Nodular
Plaque
Nodular
Nodular

Lesion Site
L. Limb
U. Limb
L. Limb
L. Limb
L. Limb
L. Limb
L. Limb
L. Limb
L. Limb
Face
L. Limb
L. Limb
L. Limb

copies/mL, **Self-reported KS duration, L – Lower, U – Upper, NR – Not Recorded, NA – Not Applicable.

*

Lack of CD8+ T-cells co-localization with LANAexpressing cells in KS tissues

but LANA+ cells, indicating that other cell types such as
fibroblast, epithelial, dendritic and B cells demonstrated to
support KSHV infection in vitro may also be present in KS
tissues in vivo (Figure 1B) [24–26].

Cytotoxic T-cells are anticipated to migrate into
areas of foreign/tumor antigens in response to chemokines,
such as CxCL-9 [27, 28]. To investigate CD8+ T-cell
infiltration, adjacent tissues sections were IHC stained
for LANA and CD8 expression, respectively. Regions
with high numbers of LANA+ cells and high CD8+ T-cells
on the adjacent slides were identified and statistically
compared (Figure 3A). Overall, there were more CD8+
T-cells in KS tissue sections compared to normal skin.
There was a lack of co-localization of cells with LANA
signal and CD8+ T-cells on the adjacent section from the
same tissue biopsy in 12 out of 13 analyzed KS tissues.
Although CD8+ T-cells were present, but they were
sparsely distributed within LANA+ regions of both EpKS
and EnKS tissues (Figure 3A), with the majority found
in regions devoid of LANA (P < 0.0001) (Figure 3B).
These results were validated with identical findings using
a different source of anti-CD8 antibody (Supplementary
Figure 1).
The use of adjacent tissues sections with traditional
single-color IHC to infer co-localization of markers
is challenging, as two sequential sections need to be
overlaid to determine co-localization. In order to solve
this challenge and re-examine the relationship between
infected cells and TIIC, we further utilized DIF to stain
for LANA and CD8+ T-cells on the same tissue section.
Consistent with the IHC results, there was a lack of colocalization of LANA+ cells and CD8+ T-cells on the same

KS tissues express chemoattractant CxCL-9
Chemokines create chemotactic gradients that
can recruit immune cells to the sites of an infection or
neoplasia [18]. Expression of T-cell chemoattractants in
tissue could suggest an attempt to recruit T-cells to tissue
sites. Alternately, these types of chemokines are often
produced by myeloid cells that have polarized phenotypes
that could be either cancer supportive, cancer repressive or
neither. Our recent comparative transcriptomics analysis
of KS biopsies versus ipsilateral/contralateral normal
skin from the same individual demonstrated that KS
lesions express significantly high levels of T-cell chemoattractants CxCL-9, 10 and 11 compared to normal skin
[17]. CxCL-9 was examined instead of CxCL-10 and
-11 because it was upregulated the most in KS lesions
vs controls skin at false discovery rate (FDR) < 5% [17].
Using DIF co-staining for LANA and CxCL-9, we found
that CxCL-9 was indeed expressed at higher levels in
both EpKS and EnKS tissue compared to normal skin,
consistent with our published transcriptomics analysis
[17] (Figure 2). Most CxCL-9 positive cells in KS tissue
were LANA- and localized in areas with reduced or
undetectable LANA expression. Overall, this suggests that
T-cell recruitment into KS is not localized to the KSHV
infected regions of both EpKS and EnKS tissues.
www.oncotarget.com

1558

Oncotarget

section (Figure 4A). While CD8+ T-cells were detectable
in LANA+ regions of the tissues, their distribution was
sparse and less abundant compared to regions devoid
of LANA (P < 0.0001) (Figure 4B). Importantly, the
proportions of CD8+ T-cells in LANA+ regions were
similar to proportions in normal skin for most tumor
biopsies (Supplementary Figure 2). However, CD4+
(Helper T-cells), CD19+ (B-cells) and CD56+ (NK cells)
cells were nearly absent in most KS tissues, and when

present, were at levels indistinguishable from levels in
normal skin tissue (data not shown). Overall, there was
lack of co-localization of CD8+, CD4+, B, or NK cells in
the vicinity of KSHV infected cells.
To investigate the potential impact of HIV-1
co-infection on TIIC infiltration into KS tissues, we
compared staining for CD8, CD4, B, and NK cells
between EpKS and EnKS patients. The dearth of CD8+
T-cell infiltration into LANA+ regions of KS biopsies in

Figure 1: (A) Representative images showing varying abundancies of Kaposi’s Sarcoma-associated Herpesvirus (KSHV) Latency

Associated Nuclear Antigen (LANA) protein on Kaposi’s Sarcoma (KS) tissues and normal skin by immunohistochemistry (IHC) staining.
Representative images at 20× and 40× magnification are shown for KS tissue with high abundance LANA positive cells ID-21242, medium
abundance LANA positive cells ID-21230, low abundance LANA positive cells ID-21229 and normal skin with no LANA positive cells IDC063-control. (B) Dual-immunofluorescence staining of Kaposi’s Sarcoma-associated Herpesvirus (KSHV) Latency Associated Nuclear
Antigen (LANA) protein and endothelial cell surface marker CD34 on Kaposi’s Sarcoma (KS) tissues ID-C3096 and normal skin ID21650. Representative images are shown, Alexa 488 (green) for LANA, Alexa 647 (red) for CD34 and 4’,6-Diamino-2-Phenylindole,
Dihydrochloride (DAPI) (blue) for nuclei staining. Pink arrow – LANA positive and CD34 positive cell, Orange arrow – LANA positive
and CD34 negative cell.
www.oncotarget.com
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EpKS was comparable to EnKS (Figure 5) and revealed
no differences in the infiltration or co-localization of
lymphocytes upon HIV-1 co-infection. Similarly, CD4
T-cells, B, and NK cells were not differential between
EpKS and EnKS patients.

were localized in LANA- regions (P = 0.0002) (Figure
6A and 6B). Interestingly, while there were less CD163+
cells in LANA+ regions than other regions for most KS
tissues, the number of CD163+ cells in LANA+ regions
were significantly higher in EpKS than in EnKS (P =
0.03) (Figure 7A and 7B). This is consistent with increased
CD163 levels of expression by the macrophages in HIV1 infection [34, 35]. However, CD163 expression in
biopsy tissue was not different between HIV-1 viremic
and aviremic EpKS subjects suggesting that ART is not
mitigating the impact of HIV-1 on CD163 upregulation
(data not shown). We also evaluated the distribution of
lectin/selectin-binding scavenger receptor, CD68 as a
marker of infiltration of KS tissue by M1/inflammatory
macrophages. Cells expressing CD68 were randomly
distributed in KS tissues and were not significantly
different between LANA+ or LANA- regions (Figure 8).
Likewise, no differences between EnKS and EpKS in
CD68+ cell distribution was evident (Figure 9). However,
the ratio of CD68 to CD163 cells was significantly
higher in LANA+ regions compared to LANA- regions

CD163 expressing cells are in LANA negative
region
Tissue resident or infiltrating macrophages can
produce chemokines, including CxCL-9, to recruit
T-cells to areas with antigens [29]. However, in the
tumor microenvironment, macrophages are also known
to produce inflammatory mediators and reactive oxygen
species that can induce angiogenesis and promote
tumor progression [30–32]. To investigate the M2/antiinflammatory macrophage distribution in KS tissues,
we evaluated the distribution of CD163, a hemoglobinhaptoglobin acute phase marker which is often correlated
with myeloid suppressor phenotypes [33]. While CD163+
myeloid cells were evident in biopsied tissue, the majority

Figure 2: Dual-immunofluorescence staining of Kaposi’s sarcoma-associated Herpesvirus (KSHV) Latency Associated
Nuclear Antigen (LANA) protein and C-X-C Motif Chemokine Ligand 9 (CxCL-9) on Kaposi’s Sarcoma (KS) tissues
ID-C3057 (LANA+ and LANA- regions) and normal skin ID-21650. Representative images are shown, Alexa 488 (green) for
LANA, Alexa 647 (red) for CxCL-9 and 4’,6-Diamino-2-Phenylindole, Dihydrochloride (DAPI) (blue) for nuclei staining. Orange arrow
– CxCL-9 positive cell.
www.oncotarget.com
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of KS biopsies (Figure 10). Taken together, macrophages
in KS tissues do not specifically localize with or target
the KSHV infected cells. Moreover, the distribution of
myeloid/macrophage cells in KS does not appear to reflect
HIV-1 co-infection status or control of HIV-1 viremia.

lesions. Consistent with expression of the known T-cell
chemoattractant, CxCL-9, in the KS tissues, there were
more CD8+ T-cells in KS tissue sections compared to
normal skin; however, it was notable that those T-cells did
not co-localize with KSHV infected cells.
CD8+ T-cells play a major role in tumor and
intracellular infection control through their capacity to
kill infected or cancer cells in response to recognition of
class I presented peptides indicative of loss of cellular
homeostasis [36]. Immunosuppression induced by the
tumor microenvironment can lead to dysfunctional CD8+
T-cells and tumor progression [37]. In solid tumors, CD8+
T-cell-mediated antitumor activity can be hindered by
inhibitory cytokines, altered metabolism, expression
of immune checkpoint molecules, abnormal tumor

DISCUSSION
This is the first study to investigate spatial
relationships between chemokine expression, immune
cell infiltration and KSHV infected cells in EpKS and
EnKS tumor tissues from SSA. Our analysis found that
in both EpKS and EnKS, the abundance and distribution
of LANA+ cells varies widely between KS biopsies even
though most of the patients in this cohort had nodular KS

Figure 3: Single-color immunohistochemical staining of adjacent KS tissue sections using mouse anti-LANA and
mouse anti-humanCD8 antibodies. (A) Representative scanned images at 2× and 40× magnification for LANA and CD8 staining
ID-C3097. Green rectangle – LANA positive region of the tissue section, red rectangle – CD8+ T-cell region of the tissue section. (B)
Quantification plots in LANA+ and CD8+ regions of the adjacent tissues sections.
www.oncotarget.com
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angiogenesis, myelosuppressive cells or regulatory T-cells
(Tregs), acting alone or in combination [37, 38]. In KS,
Tregs have been suggested to regulate CD8+ T-cells [39].
To evaluate which of these potential mechanisms might
be contributory to KS pathogenesis, we have initially
evaluated markers and cell types that were found to be
elevated in our KS transcriptomics analysis that compared
KS tissue to contralateral skin from the same subjects
[17]. That study suggested over-expression of T-cell
chemoattractant genes and those indicative of immune cell
infiltration coupled to a Warburg-like metabolic pattern.
Quantification of the extent of CD8+ T-cell infiltration

into KS tissues revealed a distribution that was limited
mainly to areas devoid of KSHV LANA+ cells. This was
surprising, since the T-cell chemoattractant, CxCL-9, was
demonstrated to be elevated at the protein level in KS
tissues sections compared to normal skin. Importantly,
other T-cell chemoattractants, CxCL-10 and 11 transcripts
were also overexpressed in KS lesions compared to
controls [17], but we have not yet attempted detection of
those proteins in tissue. While CD8+ T-cells were clearly
present in the vicinity of KS tumor tissue in excess of the
numbers in normal skin, it is possible that recruited CD8+
T-cells undergo inhibition from exposure to the cytokines

Figure 4: Dual-immunofluorescence staining of Kaposi’s Sarcoma-associated Herpesvirus (KSHV) Latency Associated
Nuclear Antigen (LANA) protein and CD8+ T-cells on Kaposi’s Sarcoma (KS) tissues. (A) Representative images are shown

ID-C038, Alexa 488 (green) for LANA, Alexa 647 (red) for CD8 and 4’,6-Diamino-2-Phenylindole, Dihydrochloride (DAPI) (blue) for
nuclei staining. (B) Quantification plot for the percentage CD8 positive cells per field of view. Red horizontal lines indicate median. (+) –
Positive and (–) – Negative. Orange arrow – CD8 positive T-cell.
www.oncotarget.com
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produced by the tumor cells like IL-10 and TGF-β, that
may impede access to the tumor parenchyma [17, 38].
Like other herpesviruses, KSHV is known to
downregulate MHC class I antigen presentation and
T-cell co-stimulation molecules CD86 and ICAM [40,
41]. Through viral encoded K3 and K5, KSHV escapes
detection by cytotoxic T-cells and NK cells [42, 43].
vIRF3 also downregulates MHC class II by degrading
interferon-γ produced by NK cells [44]. It is possible that
the lack of T-cell co-localization with KSHV infected
cells in KS tumors is a result of KSHV downregulation
of interferon responses and antigen presentation. The
lack of co-localization could also be due to the lack
of T-cell repertoire against KSHV in the T-cells that
chemotactically locate the infected cells in the KS tumor.
Studies of circulating T-cell Ag-specific function suggest
lack of immunodominance against KSHV antigens in

either KS or asymptomatic patients. Although some T-cell
repertoire against KSHV has been reported, most of these
responses were weak and variable in different individuals
[45, 46]. It is also possible that the viral peptides presented
by Class I on the KS tumors are decoupled from T-cell
repertoire recognition, thereby shielding the antigens from
the immune systems. This is currently under investigation.
KSHV is known to induce hypoxic metabolic
derangements through HIF-1 expression [47]. The
induced metabolic dysfunctions, including Warburglike metabolism, could result in lactate production. The
resultant hypoxic and acidic tumor environment could be
non-conducive for T-cell infiltration leading to restriction
of CD8+ T-cells access. Although, it appears unlikely given
the progressive nature of KS disease, it is also possible
that LANA+ cells were previously targeted and killed by
CD8+ T-cells in regions exhibiting enriched T-cells but

Figure 5: Dual-immunofluorescence staining of Kaposi’s Sarcoma-associated Herpesvirus (KSHV) Latency Associated
Nuclear Antigen (LANA) protein and CD8+ T-cells on Kaposi’s Sarcoma (KS) tissues. (A) Representative images are
shown EnKS – ID-C063 and EpKS – ID-C038, Alexa 488 (green) for LANA, Alexa 647 (red) for CD8 and 4’,6-Diamino-2-Phenylindole,
Dihydrochloride (DAPI) (blue) for nuclei staining. (B) Quantification plot for the percentage CD8 positive cells per field of view. Red
horizontal lines indicate median. (+) – Positive and (–) – Negative. EnKS – Endemic KS and EpKS – Epidemic KS. Orange arrows – CD8
positive T-cells.
www.oncotarget.com
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devoid of LANA+ cells. However, T-cells in these focal
areas would have to have become exhausted and unable to
proliferate and infiltrate the rest of the tumor [48]. Further
studies will be needed to address the immunophenotypes,
functionality and KSHV specificity of the CD8+ T-cells
and other immune cells from the immune cell infiltrates in
KS biopsies. Analysis of MHC class I peptides presented
on KS tumors is also important in order to rule out
mismatch between T-cell repertoire and Ag presentation
repertoire.
Macrophages detect, engulf and destroy invading
microorganisms and infected cells [31, 49]. During tumor
progression, tumor cells induce maladaptive macrophage
phenotypes through metabolic reprogramming [50]. The
maladapted macrophages create an immunosuppressive
niche leading to tumor progression and therapeutic

resistance [51]. Cytokines such as IL-6, IL-10 and
TGF-β are known to polarize macrophages into the M2
phenotype that is associated with immunosuppression
[9, 30, 52]. Interestingly our previous study has shown
that IL-6, IL-10, IL-5 and TGF-β were elevated in
KS patients compared to asymptomatic controls [5].
These cytokines were also associated with increased
antibody responses that are not protective against KS
[5]. High levels of macrophages in KS biopsies could
be responsible for creating an immunosuppressive niche
that restricts CD8+ T-cell infiltration and enhance tumor
growth. Overall, it appears that macrophages in KS
tumors support KS progression. However, investigation
of different macrophage phenotypes and their specific
functions in KS biopsies is needed to understand the role
of TIIC in KS.

Figure 6: Dual-immunofluorescence staining of Kaposi’s Sarcoma-associated Herpesvirus (KSHV) Latency Associated
Nuclear Antigen (LANA) protein and CD163 on Kaposi’s Sarcoma (KS) tissues. (A) Representative images are shown, Alexa
488 (green) for LANA, Alexa 647 (red) for CD163 and 4’,6-Diamino-2-Phenylindole, Dihydrochloride (DAPI) (blue) for nuclei staining
ID-C063. (B) Quantification plot for the percentage CD163 positive cells per field of view. Red horizontal lines indicate median. (+) –
Positive and (–) – Negative. Orange arrows – CD163 positive cells.
www.oncotarget.com
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This study initiated the investigation of TIIC in
KS biopsies in order to understand the role of TIIC in
KS. Overall, there is poor immune cell infiltration or
co-localization in LANA+ regions of KS biopsies. The
apparent lack of immune cell co-localization with KSHV
infected cells for both EpKS and EnKS suggests that HIV-1
does not significantly influence immune cell infiltration in
KS biopsies. However, the size of the cohort, the formalinfixed treatment of the samples as well as the limited tumor
and control tissue quantity, have reduced the depth of our
investigations. Studies with larger sample sizes patients
will be needed to address gaps highlighted in this study.
Whether TIICs in KS are functional and match presented
peptides in the tumor also need to be further investigated
with freshly collected tissue. Correlation between TIIC

abundance and treatment outcomes of KS could be useful
in defining the role of TIIC as a prognostic marker of KS.

MATERIALS AND METHODS
Study design, subjects and samples
This cross-sectional study recruited 16 participants
(4 EnKS, 9 EpKS KS patients and 3 controls without
KS) from Tanzania and Zambia. Participants were of
both genders and over 18 years old. Written informed
consent was obtained from all study participants. KS was
diagnosed by both histology and immunohistochemistry
for KSHV latency associated nuclear antigen (LANA).
Peripheral blood samples about 10 mL were collected,

Figure 7: Dual-immunofluorescence staining of Kaposi’s Sarcoma-associated Herpesvirus (KSHV) Latency Associated
Nuclear Antigen (LANA) protein and CD163 on Kaposi’s Sarcoma (KS) tissues. (A) Representative images are shown
EnKS – ID-C3096 and EpKS – ID-C038, Alexa 488 (green) for LANA, Alexa 647 (red) for CD163 and 4’,6-Diamino-2-Phenylindole,
Dihydrochloride (DAPI) (blue) for nuclei staining. (B) Quantification plot for the percentage CD163 positive cells per field of view. Red
horizontal lines indicate median. (+) – Positive and (–) – Negative. EnKS – Endemic KS and EpKS – Epidemic KS. Orange arrow – CD163
positive cells.
www.oncotarget.com
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HIV-1 serology and plasma viral load
quantification by real-time PCR (RT-PCR)

plasma was isolated and used for HIV-1 viral load
quantification by real-time PCR. A 4 mm KS biopsy
was taken from each subject, fixed in neutral buffered
formalin, and processed into a paraffin-embedded block
for KS histological diagnosis, LANA IHC and subsequent
immunofluorescence staining. This study was approved
by the review boards of Tanzania National Institute
for Medical Research, Ocean Road Cancer Institute,
University of Zambia Biomedical Research Ethics
Committee and the University of Nebraska-Lincoln
(UNL).

HIV-1 serology was determined by point-of-care
serology and plasma viral load by quantitative RT-PCR
as previously described [5]. Briefly, HIV-1 screening was
done using HIV Rapid Test Algorithm in Tanzania or
Alere Determine HIV-1/2 Ag/Ab Combo test in Zambia
[53]. Viral RNA was extracted from plasma according
to the QIAamp viral RNA extraction protocol (Qiagen,
Hilden, Germany). The viral copy numbers were then

Figure 8: Dual-immunofluorescence staining of Kaposi’s Sarcoma-associated Herpesvirus (KSHV) Latency Associated
Nuclear Antigen (LANA) protein and CD68 on Kaposi’s Sarcoma (KS) tissues. (A) Representative images are shown IDC038, Alexa 488 (green) for LANA, Alexa 647 (red) for CD68 and 4’,6-Diamino-2-Phenylindole, Dihydrochloride (DAPI) (blue) for
nuclei staining. (B) Quantification plot for the percentage CD68 positive cells per field of view. Red horizontal lines indicate median. (+)
– Positive and (–) – Negative. Orange arrows – CD68 positive cells.
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determined using RNA Ultra-Sense One-Step quantitative
RT-PCR system (Applied Biosystems, Carlsbad, CA) as
previously described with universal HIV LTR primers [54]
(forward [5′-GCCTCAATAAAGCTTGCCTTGA-3′] and
reverse [5′–GGGCGCCACTGCTAGAGA–3′] and probe
[5′-FAM/CCAGAGTCACACAACAGACGGGCACA/BHQ1-3′]) under the following conditions: 50°C for 15
min, 95°C for 2 min, 40 cycles of 95°C for 15 seconds,
and 60°C for 30 seconds.

LNA (1:100) (Leica Biosystems, Newcastle, UK), antihuman CD8 clone C8/144B (1:100) (Agilent, Santa Clara,
CA) or anti-human CD8 clone 4B11 (1:40) (GeneTex,
Irvine, CA) were used as primary antibodies. Normal
mouse IgG (Dako ×0931, Agilent, Santa Clara, CA) was
used as an isotype control at identical concentration.
To quantify the number of positive cells for a specific
cell surface marker of interest, all IHC stained slides were
digitally scanned on a MoticEasyScan One (Motic, San
Antonio, TX) at 40 ×. On each anti-LANA stained slide,
five regions of about 50 µm2 were selected in regions with
high abundance of LANA. The total number of cells and
LANA+ cells were then quantified using Fiji software
(NIH). The same procedure was applied to anti-CD8 stained
slides and CD8+ cells were counted. The five high LANA
regions were then identified on corresponding CD8 stained

Immunohistochemistry (IHC) and cell
quantification
Adjacent 6 µm-thick sections of paraffin-embedded
KS tissues were used for IHC, as previously described
[55]. Mouse anti-LANA antibody clone NCL-L-HHV8-

Figure 9: Dual-immunofluorescence staining of Kaposi’s Sarcoma-associated Herpesvirus (KSHV) Latency Associated
Nuclear Antigen (LANA) protein and CD68 on Kaposi’s Sarcoma (KS) tissues. (A) Representative images are shown IDC038, Alexa 488 (green) for LANA, Alexa 647 (red) for CD68 and 4’,6-Diamino-2-Phenylindole, Dihydrochloride (DAPI) (blue) for
nuclei staining. (B) Quantification plot for the percentage CD68 positive cells per field of view. Red horizontal lines indicate median. (+)
– Positive and (–) – Negative. EnKS – Endemic KS and EpKS – Epidemic KS. Orange arrows – CD68 positive cells.
www.oncotarget.com

1567

Oncotarget

slides and the total number of cells and CD8+ T-cells were
counted. Reciprocally, the five high CD8+ regions were
then identified on corresponding LANA stained slides and
the total number of cells and LANA+ cells were counted.
Average number of total cells and marker-delineated cells
in the five regions were used to calculate proportions of
specific markers in an area of high LANA or high CD8+
T-cells on adjacent tissue sections. Percentages of specific
markers were then calculated and plotted using GraphPad
Prism v.5 (GraphPad Software, San Diego, CA).

anti-rat A21208 together with either Alexa 647-Donkey
anti-mouse A31571 (Invitrogen, Eugene, OR) or Alexa
647-Donkey anti-goat A32849, Invitrogen, Rockford IL) for
2 hours at room temperature in a humidity chamber. Nucleus
counterstaining was performed with 300 nM 4’,6-Diamino-2Phenylindole, Dihydrochloride (DAPI) solution (Invitrogen
D1306, Eugene OR) for 30 minutes before mounting
coverslip with Fluoro-gel (# 17985-10, Electron Microscopy
Sciences, Hatfield PA). To determine lineage of the KSHV
infected cells in the KS tumors, endothelial cell marker
CD34 was utilized, consistent with other literature on KS
where CD34 has been utilized to demonstrate endothelial
lineage [22, 23].

Dual-Color Immunofluorescence (DIF)
Adjacent 6 µm-thick sections of paraffin-embedded
KS tissues were processed following the IHC protocol with
modifications. After antigen retrieval, the sections were
incubated with 0.3M glycine for 30 min at room temperature
to minimize tissue auto-fluorescence and Tris-NaCl blocking
buffer (PerkinElmer FP1020, Boston, MA) was used as
blocking solution. For DIF, a rat anti-LANA antibody clone
LN35 at 1:100 (Abcam, Cambridge, MA) was used together
with one of the following primary mouse monoclonal
antibodies: anti-CD8 clone C8/144B (1:100), anti-CD4 clone
4B12 (1:100), anti CD34 clone QBEnd10 (1:50), anti-CD68
clone KP1 (1:100), CD19 clone LE-CD19 and anti-CD56
clone 123C3 (1:100) (Agilent, Santa Clara, CA) and antiCD163 clone10D6 (1:100) (Novus Biologicals, Centennial,
CO) or goat polyclonal anti-CxCL-9/MIG clone AF392
(R&D systems, Minneapolis, MN). The primary antibodies
were diluted in TNB blocking buffer and incubated at 4°C
overnight in a humidity chamber. Sections were equilibrated
to room temperature, rinsed in 1× PBS-0.05% Tween-20 and
then incubated with secondary antibodies Alexa 488-Donkey

Confocal microscopy and cell quantification
All sections were imaged with Nikon A1R laser
scanning confocal system mounted on Nikon Ti2 inverted
fluorescence microscope (Nikon Instruments, Melville,
NY). Nuclei stained with DAPI were excited at 405 nm
wavelength and emission was collected between 425–475
nm wavelengths. Alexa 488 stained LANA was excited at
488 nm wavelength and emission was collected between
500–550nm wavelengths. All other surface markers
were stained with Alexa 647, and excited at 640 nm with
emission collection between 663–738 nm wavelengths.
Images were acquired with NIS elements software (Nikon
Instruments, Melville, NY) using sequential scanning
(channel series) and Z-stacking (Z-series) of 1 µm slices at
60× magnification. Settings for laser power, detector gain
and offset for individual markers were unchanged between
slides. LANA positive (+) and negative (–) regions were
identified in the same tissue and three representative

Figure 10: The ratio of CD68 to CD163 cells in LANA+ and LANA- regions of KS biopsies. (+) – Positive and (–) – Negative.
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